SCHEMBL3790258

SCHEMBL3790258

CCOC(=O)c1cccc2c1nc(Nc1ccccc1F)c1cncn12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 10/20 0.55
PIM1 P11309 3/20 0.53
PIM2 Q9P1W9 3/20 0.53
CSNK2B P67870 1/20 0.53
CSNK2A1 P68400 1/20 0.53
LYN P07948 3/20 0.44
BTK Q06187 3/20 0.44
KDM4E B2RXH2 1/20 0.42
FLT3 P36888 1/20 0.42
BAD Q92934 1/20 0.42
CDC25A P30304 1/20 0.42
CDC25B P30305 1/20 0.42
CDC25C P30307 1/20 0.42
ALDH1A1 P00352 1/20 0.42
TSHR P16473 1/20 0.41
ABL1 P00519 1/20 0.41
EGFR P00533 1/20 0.41
FYN P06241 1/20 0.41
SRC P12931 1/20 0.41
EPHA8 P29322 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3790215 0.88 PIM1 (0.50) PIM1PIM2CSNK2BCSNK2A1KDM4E
SCHEMBL13057012 0.85 LCK (0.63) LCKPIM1PIM2CSNK2BCSNK2A1
SCHEMBL13057014 0.84 LCK (0.61) LCKPIM1PIM2CSNK2BCSNK2A1
SCHEMBL3794469 0.83 KDM4E (0.46) PIM1PIM2CSNK2BCSNK2A1KDM4E
SCHEMBL3784214 0.78 LCK (0.54) LCKKDM4ECDC25BALDH1A1TSHR
SCHEMBL7981902 0.72 LCK (1.00) LCKPIM1PIM2CSNK2BCSNK2A1
SCHEMBL3790221 0.72 CDC25B (0.44) PIM1PIM2CSNK2BCSNK2A1KDM4E
SCHEMBL3789556 0.72 PIM1 (0.56) LCKPIM1PIM2CSNK2BCSNK2A1
SCHEMBL3789809 0.69 PIM1 (0.70) LCKPIM1PIM2CSNK2BCSNK2A1
SCHEMBL928951 0.68 SMN1; SMN2 (0.47) KDM4ECDC25ACDC25BCDC25CALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010135571-A1 NOVEL PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
WO-2010135571-A1 NOVEL PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS PIM2, PIM1, PIM3 LCK 49/4885PIM1 2/4885PIM2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.